Hubbry Logo
Amino estersAmino estersMain
Open search
Amino esters
Community hub
Amino esters
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Amino esters
Amino esters
Amino esters
View on Wikipedia
from Wikipedia

Amino esters are a class of local anesthetics. They are named for their ester bond and are unlike amide local anaesthetics.

Structure

[edit]

Structurally, amino esters consist of three molecular components:

The chemical linkage between the lipophilic part and the intermediate chain can be of the amide-type or the ester-type, and is the general basis for the current classification of local anesthetics.

Amino esters, in reference to anesthetic agents, are rapidly metabolized in the plasma by butyrylcholinesterase to para-aminobenzoic acid derivatives, then excreted in the urine. This suggests their very short half lives. Allergy is more likely to occur with ester-type agents, as opposed to amide-type.

Examples

[edit]

Amino ester-type include:

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Amino esters

View on Grokipedia
from Grokipedia
Amino esters are a class of local anesthetics featuring an ester bond that links an aromatic acid to a dialkylamino alcohol, enabling their classification separate from amino local anesthetics. The class includes the naturally occurring and synthetic compounds developed primarily in the early 20th century as safer alternatives to ; notable examples include (introduced in 1900), (1905), (1930), and (1955). They exert their effects by reversibly blocking voltage-gated sodium channels in membranes, thereby inhibiting the propagation of action potentials and providing localized analgesia. Unlike amino amides, amino esters are rapidly hydrolyzed by plasma pseudocholinesterases into metabolites like para-aminobenzoic acid (PABA), resulting in shorter durations of action but a higher risk of allergic reactions due to the immunogenic nature of these breakdown products. Clinically, they are employed for infiltration, topical, spinal, and epidural anesthesia in short procedures, with often used for mucosal numbing and for minor surgeries, though their use has declined in favor of more stable amides owing to instability in solution and allergy concerns.

Overview

Definition

Amino esters are a subclass of local anesthetics defined as organic compounds featuring both an amino group and an , particularly those in which an ester bond connects a lipophilic aromatic ring to an intermediate chain terminating in a hydrophilic tertiary amine. This structural configuration enables them to block sodium channels in membranes, thereby inhibiting impulse conduction for localized relief. In the broader context of local anesthetics, amino esters exemplify the general motif of a lipophilic aromatic portion linked to a hydrophilic via an intermediary chain. A key distinction of amino esters from the related subclass of amino lies in the nature of the intermediary linkage: amino esters incorporate an (-COO-) bond, whereas amino amides feature an (-CONH-) bond. This difference influences their , with amino esters undergoing rapid by plasma pseudocholinesterase enzymes, often producing para-aminobenzoic acid as a metabolite that can trigger allergic reactions. In contrast, amino amides are primarily metabolized in the liver by enzymes, resulting in greater stability and a lower incidence of . The naming convention for amino esters originated in the early amid pivotal discoveries in chemistry, building on the identification of cocaine's in the late and subsequent synthesis of safer alternatives. For instance, , an ethyl of , was synthesized in 1900 by German Eduard Ritsert and introduced to the market in 1902, while —a prototypical amino —was synthesized in 1905 by Alfred Einhorn as a less toxic substitute for . These innovations, driven by efforts to mitigate cocaine's addictive and cardiovascular risks, established the amino ester class as a foundational category in by emphasizing the linkage's role in efficacy and .

Role in Local Anesthesia

Amino esters serve as a key subclass of , functioning primarily through the reversible blockade of voltage-gated sodium channels in neuronal membranes, which inhibits the influx of sodium ions necessary for generation and propagation, thereby preventing the transmission of signals along fibers. This targeted inhibition allows for localized numbing without affecting , making amino esters essential for intraoperative and procedural . The in amino esters distinguishes them from other anesthetics and predisposes them to rapid by plasma pseudocholinesterases, resulting in a short duration of action that aligns well with brief medical interventions such as minor surgeries or dental procedures. This pharmacokinetic profile minimizes the risk of prolonged systemic exposure, enhancing their safety for short-term applications. Relative to amide-type local anesthetics, amino esters typically have a shorter duration of action because of the swift metabolic breakdown. For instance, , a prototypical amino ester, achieves onset in 2-5 minutes but provides analgesia for only 30-60 minutes, in contrast to amides like lidocaine, which offer similar onset but extend up to 120 minutes.

Chemical Structure

Molecular Components

Amino ester local anesthetics, a subclass of ester-type agents used in regional , typically feature a tripartite molecular architecture comprising a lipophilic aromatic ring, an intermediate -linked alkyl chain, and a hydrophilic group, each contributing uniquely to their pharmacological . This structure enables the drugs to partition between aqueous and phases, facilitating across sheaths and interaction with voltage-gated sodium channels to produce reversible blockade. Note that while this describes the prototypical structure (e.g., in and ), is an exception, featuring a primary amino group on the aromatic ring and a simple ethyl without a terminal or extended alkyl chain. The lipophilic aromatic ring, typically a derivative substituted with groups such as amino or alkoxy moieties (as in or ), promotes in environments and enhances membrane penetration by allowing the uncharged form of the molecule to traverse the bilayer of neuronal . This component is essential for the initial phase of action, as higher correlates with increased potency; for instance, modifications to the ring increase the , thereby amplifying the drug's ability to reach intracellular targets. The hydrophilic group is typically a tertiary dialkylamino moiety that provides a basic site that protonates at physiological (around 7.4), yielding a positively charged quaternary with a pKa typically in the range of 8.0–9.0. This facilitates electrostatic binding to the intracellular mouth of sodium channels, while the un-ionized fraction (governed by the pKa) supports extracellular , creating an optimal balance for onset and efficacy; agents with lower pKa values exhibit faster onset due to a greater un-ionized proportion at neutral . Connecting the aromatic ring and amine group, the intermediate alkyl —formed via an ester bond—serves as a flexible linker whose and substitution pattern modulate the molecule's overall conformation, influencing potency and duration of . Shorter chains may enhance rigidity for tighter channel binding, while longer ones improve and prolong action by altering steric interactions; this also contributes to the pKa-lipid equilibrium by fine-tuning hydrophilicity, ensuring the molecule maintains sufficient aqueous for vascular transport without compromising lipid partitioning.

General Formula

Amino esters, a subclass of local anesthetics, are characterized by a general of Ar-COO-(CH₂)ₙ-NR₂ (where Ar represents a lipophilic aromatic group, typically a substituted ring; n denotes the length of the alkyl chain linking the ester to the amine, usually 2-4 methylene units; and NR₂ is typically a hydrophilic dialkylamino group with R as alkyl substituents such as methyl or ethyl), though follows a simpler as the ethyl ester of : p-H₂N-C₆H₄-COO-CH₂CH₃, lacking the extended chain and terminal dialkylamino group. This enables the molecule to partition between aqueous and phases, facilitating interaction with neuronal membranes. Variations in substituents on the aromatic ring, such as amino (-NH₂) or alkoxy (-OR) groups in the para position, modulate the compound's ; electron-donating groups like these enhance hydrophobicity, improving membrane penetration and anesthetic potency, as seen in where the para-amino substituent contributes to balanced lipid solubility. Conversely, electron-withdrawing substituents (e.g., ) can fine-tune , often increasing duration of action by altering the molecule's overall polarity without disrupting the core framework. The linkage (-COO-) in this formula is the defining feature distinguishing amino esters from amino , which instead feature an bond (-CONH-); this group imparts hydrolytic instability in plasma via enzymes, leading to rapid compared to the more counterparts. Textually, the core architecture can be depicted as:

Ar - C(=O) - O - (CH₂)ₙ - NR₂

Ar - C(=O) - O - (CH₂)ₙ - NR₂

where the moiety bridges the aromatic and domains, underscoring the class's pharmacokinetic profile.

Properties

Physical and Chemical Properties

Amino esters, as a class of compounds featuring an linkage between an aromatic and an amino alcohol, typically appear as colorless to pale yellow oils or low-melting crystalline solids, depending on the specific groups and whether in or salt form. These substances exhibit limited in their neutral state due to their lipophilic nature but become readily soluble at low values, where the tertiary group undergoes to form water-soluble cations. Boiling points for representative amino esters, such as and , are estimated in the range of 350–410 °C at standard , influenced by molecular weight and alkyl chain length, though many decompose before reaching these temperatures. Chemically, the moiety imparts susceptibility to in aqueous environments, particularly under acidic or basic conditions, resulting in the formation of the corresponding and amino alcohol. These compounds maintain stability in dry, neutral conditions but are prone to degradation when exposed to elevated temperatures or acidic media, which accelerate ester bond cleavage. The pKa of the tertiary group in amino esters generally falls between 8.0 and 9.0, governing the equilibrium between ionized and non-ionized forms and thereby influencing and partitioning behavior in different media. For instance, has a pKa of approximately 8.9, while tetracaine's is around 8.3.

Stability and Reactivity

Amino esters demonstrate limited , particularly in the presence of moisture, where the ester linkage undergoes pH-dependent to yield an alcohol and a derivative, such as para-aminobenzoic acid from . This degradation is accelerated under acidic or basic conditions, with base-catalyzed (saponification) leading to irreversible cleavage of the ester bond. Exposure to light can further promote decomposition, resulting in discoloration and reduced potency, as observed in solutions of and . To mitigate these stability issues, amino esters are typically formulated and stored as hydrochloride salts, which enhance and resistance to in dry conditions. Storage recommendations include airtight containers to prevent moisture ingress, maintenance at (15–30°C), and protection from direct to preserve integrity over time. Discolored solutions should be discarded, as they indicate degradation. Regarding reactivity, amino esters are prone to saponification when treated with bases, forming water-soluble carboxylate salts and alcohols through nucleophilic attack at the carbonyl carbon. They also exhibit potential for transesterification in the presence of alcohols and catalysts, exchanging the alkoxy group while retaining the acyl component./Esters/Reactivity_of_Esters/Transesterification) In most organic solvents, amino esters remain inert, showing no significant reactivity, but the ester carbonyl is susceptible to nucleophiles, enabling acyl substitution reactions under appropriate conditions. In contrast to amino amides, which feature a more robust linkage resistant to , amino esters degrade more readily in hydrolytic environments, contributing to their shorter and necessitating careful handling.

Synthesis

Laboratory Methods

In laboratory settings, amino esters, particularly those used as local anesthetics, are synthesized on a small scale through targeted esterification reactions that couple p-aminobenzoic acid derivatives with amino alcohols or simple alcohols. These methods prioritize high purity and ease of handling in research environments, often employing classical organic techniques to form the linkage while managing the reactivity of the amino groups. strategies, such as using nitro derivatives, are commonly applied to prevent side reactions during bond formation. A widely adopted route involves the esterification of p-aminobenzoic acid derivatives using acid chlorides, exemplified by the preparation of procaine. In this approach, p-nitrobenzoyl chloride—a nitro-protected derivative of p-aminobenzoic acid—is reacted with 2-diethylaminoethanol in an inert solvent like dichloromethane or toluene at 0–25°C to minimize self-reaction of the acid chloride. The reaction proceeds via nucleophilic acyl substitution, typically completing within 1–2 hours with yields of 85–95% for the intermediate nitro ester (nitrocaine), isolated by aqueous extraction and evaporation under reduced pressure. Subsequent reduction of the nitro group to the free amino functionality is achieved using tin powder in concentrated hydrochloric acid at reflux for 2–4 hours, or alternatively via catalytic hydrogenation with palladium on carbon at 50–60°C and 3–5 bar hydrogen pressure, affording procaine hydrochloride in 80–90% yield from the intermediate. The product is purified by recrystallization from hot water or ethanol-water mixtures, resulting in white crystals with melting point 155–158°C. This two-step sequence, originally developed by Alfred Einhorn in 1905, remains a benchmark for laboratory-scale synthesis due to its simplicity and efficiency. For simpler amino esters lacking a basic amino group in the alcohol component, such as benzocaine, an adapted Fischer esterification is employed directly on p-aminobenzoic acid without initial protection, though nitro protection followed by reduction is an alternative for consistency. The unprotected acid (1 equiv) is suspended in excess absolute ethanol (10–15 equiv) with 5–10 mol% concentrated sulfuric acid or hydrochloric acid as catalyst, and the mixture is refluxed for 60–90 minutes to drive ester formation via protonation of the carbonyl and nucleophilic attack by ethanol. Yields typically range from 60–80% after cooling, neutralization with sodium carbonate to pH 8–9, filtration of the precipitated ester, and washing with cold water. Further purification involves recrystallization from a minimal volume of hot ethanol or ethanol-water (1:1), yielding colorless needles with a melting point of 88–92°C. When adaptation for protected acids is necessary—such as for alcohols prone to protonation—the amino group is first converted to a nitro or acetyl protecting group; the protected carboxylic acid undergoes Fischer esterification under similar reflux conditions in ethanol with acid catalyst (e.g., HCl, 4–6 hours), followed by deprotection via zinc/acetic acid reduction or hydrolysis, achieving overall yields of 50–75% after recrystallization. This method emphasizes conceptual control of equilibrium via excess alcohol and acid catalysis, suitable for educational and research labs.

Pharmaceutical Production

The development of amino ester local anesthetics marked a significant shift in pharmaceutical production during the early , transitioning from reliance on natural extracts to synthetic alternatives. , isolated in the 1860s, was the first effective local anesthetic but posed risks due to its addictive properties and variable purity from plant sources. In 1905, German chemist Alfred Einhorn synthesized , the first widely adopted synthetic amino ester, as a safer, non-addictive substitute derived from p-aminobenzoic acid. This innovation, introduced clinically by Heinrich Braun in 1905, spurred industrial-scale manufacturing of and related compounds, reducing dependence on by the 1920s. Due to the preference for more stable amino amide anesthetics, large-scale production of amino esters such as and has diminished since the mid-20th century, with synthesis now primarily for niche or legacy applications. Where produced, esterification typically involves reacting p-aminobenzoic acid derivatives with amino alcohols like 2-diethylaminoethanol under controlled conditions using traditional batch processes, adhering to (GMP) standards as outlined by the FDA and ICH Q7 guidelines. While continuous flow reactors have been explored in research to enhance efficiency, reduce reaction times, and improve yield consistency, they are not routinely employed in commercial production of these compounds. GMP compliance mandates facilities certified for active pharmaceutical ingredient (API) production, ensuring product purity exceeds 99% through rigorous validation of processes, equipment, and analytical testing. To address impurities like p-aminobenzoic acid, which can arise from during synthesis or storage, contemporary production incorporates for real-time monitoring and adjustment of reaction parameters. Automated systems, including in-line and feedback loops, optimize ester formation and prevent degradation, maintaining impurity levels below 0.1% as per pharmacopeial limits. This approach not only supports output for remaining formulations but also aligns with regulatory requirements for traceability and in GMP-certified plants.

Pharmacology

Mechanism of Action

Amino esters, as a class of local anesthetics, exert their effects primarily by binding to voltage-gated sodium channels in their open or activated state, thereby inhibiting sodium ion influx and preventing necessary for impulse . This state-dependent occurs preferentially during the activated conformation of the channel, allowing amino esters to suppress action potentials in excitable tissues such as and without affecting resting . The interaction stabilizes the inactivated state of the channel, reducing the excitability of neurons and producing reversible . The access of amino esters to their intracellular on sodium channels involves a pH-dependent . Administered as water-soluble salts, these agents exist predominantly in their ionized (protonated) form at neutral , but a small fraction equilibrates to the un-ionized (neutral) base, which is lipid-soluble and capable of diffusing across the nerve membrane into the axoplasm. Once inside the more acidic axoplasm, the un-ionized base reprotonates to the charged cationic form, which then binds to the channel's receptor site from the intracellular side, effectively blocking sodium conductance. This mechanism explains the enhanced efficacy of amino esters in less acidic environments and their reduced potency in inflamed tissues where local is lowered. Structure-activity relationships among amino esters significantly influence their pharmacological profile. The ester linkage in their molecular structure renders them susceptible to rapid hydrolysis by plasma cholinesterases, producing metabolites like para-aminobenzoic acid that contribute to shorter durations of action compared to amide analogs; for instance, procaine's brief effect stems from this enzymatic breakdown. Potency is modulated by substitutions on the aromatic ring, where electron-donating or aliphatic groups enhance lipid solubility, facilitating membrane penetration and increasing binding affinity to sodium channels, as seen in derivatives like tetracaine with para-butyl substitutions. These modifications prioritize balanced hydrophobicity for optimal anesthetic efficacy without excessive toxicity.

Pharmacokinetics

Amino esters, a subclass of local anesthetics, exhibit distinct pharmacokinetic profiles characterized by rapid systemic clearance, primarily due to their ester linkage, which renders them susceptible to enzymatic in the bloodstream. Unlike amino amides, which undergo hepatic , amino esters are processed primarily in the plasma by pseudocholinesterase, leading to shorter durations of action and lower risk of accumulation in patients with hepatic impairment. Absorption of amino esters occurs rapidly following injection or topical application, with the rate influenced by the site of administration, vascularity, and use of vasoconstrictors like epinephrine. For infiltration , onset typically ranges from 1 to 5 minutes, as seen with , allowing quick blockade of sensory . Topical application on mucous membranes also promotes swift uptake, though intact limits absorption. Distribution of amino esters involves variable , ranging from low for agents like (~6%) to high for (~75%), which affects their free fraction and tissue penetration; for example, demonstrates approximately 75% binding. These agents distribute primarily to well-perfused tissues but cross the blood-brain barrier only minimally due to their rapid and physicochemical properties, reducing effects at therapeutic doses. Metabolism of amino esters occurs via in plasma by (butyrylcholinesterase), yielding inactive metabolites such as para-aminobenzoic acid (PABA) from and . This process is efficient, resulting in very short plasma half-lives; , for instance, has a half-life of 30-90 seconds in adults. Genetic variations in pseudocholinesterase activity can prolong this phase, though such cases are rare. Elimination primarily involves renal excretion of the hydrolyzed metabolites, with negligible unchanged recovered in , distinguishing amino esters from amino amides that rely on hepatic clearance. This plasma-based and renal elimination pathway ensures minimal hepatic involvement, making amino esters suitable for patients with liver dysfunction.

Clinical Applications

Types of Procedures

Amino esters, a class of local anesthetics, are employed in various medical procedures to provide targeted numbness by blocking conduction in specific tissues. Infiltration anesthesia involves injecting amino esters directly into tissues to numb a localized area, commonly used for minor surgical interventions such as suturing wounds or repairing lacerations. Spinal anesthesia utilizes amino esters like , administered into the , to achieve numbness of the lower body; this technique is frequently applied in , such as during cesarean sections, or for procedures on the lower extremities and abdomen. Epidural and caudal anesthesia commonly employ , administered into the , for short-duration procedures including labor analgesia and emergency cesarean sections. Topical application of amino esters, such as , is standard for anesthetizing mucous membranes, particularly in dental procedures like scaling, root planing, or cavity restorations to alleviate discomfort during examinations or minor treatments. Amino esters like are used in ocular for topical during short procedures such as tonometry or foreign body removal, but with caution due to risks of corneal with prolonged application.

Dosage and Administration

Amino esters, such as and , are typically administered via injectable or topical routes, with preparations formulated as salts to enhance aqueous solubility and stability. Injectable forms are used for infiltration, peripheral nerve blocks, and neuraxial anesthesia, while topical applications include gels, ointments, sprays, or ophthalmic solutions for surface anesthesia. For procaine, common concentrations range from 0.25% to 2% solutions for infiltration and , with dosages of 350 to 600 mg (7 to 10 mg/kg) not exceeding a total of 1 g per procedure to minimize systemic absorption risks. In neuraxial , a 10% solution is employed at doses of 50 to 200 mg, depending on the desired sensory level. is often used at 1% for injectable spinal , with doses of 15 to 20 mg (1.5 to 2 mL) injected intrathecally at the L2 to L4 interspace, rarely exceeding 15 mg; topically, 0.5% to 1% solutions or gels are applied, limited to 1 g per site for procedures. Dosing is influenced by patient factors including age, weight, and hepatic or renal function, as well as the injection site—highly vascular areas like the or genitals may require reduced doses due to faster absorption. The addition of vasoconstrictors such as epinephrine (1:200,000) to solutions can extend duration and allow up to a 50% increase in maximum dose by slowing vascular uptake, particularly for infiltration techniques. Always initiate with the lowest effective dose, administered incrementally with aspiration to avoid intravascular injection.

Examples

Procaine and Derivatives

Procaine, marketed as Novocain, represents the prototypical amino local anesthetic, synthesized in 1905 by Alfred Einhorn as a safer alternative to for . Its chemical structure, 2-(diethylamino)ethyl 4-aminobenzoate, consists of a p-aminobenzoic acid linked to a diethylaminoethanol moiety, exemplifying the general amino framework where an aromatic is esterified with a hydrophilic amino alcohol. This compound gained widespread adoption for its rapid onset and intermediate duration of action, primarily employed in dental procedures and local infiltration to block nerve conduction by inhibiting sodium influx in neuronal membranes. Key derivatives of include and propoxycaine, which modify the parent structure to alter pharmacokinetic profiles while retaining the ester linkage susceptible to . , synthesized in , features a chlorine substitution at the ortho position of the ring, accelerating its by plasma pseudocholinesterase by 3- to 4-fold compared to , thereby yielding a shorter duration of (typically 30-60 minutes) and reduced systemic toxicity risk. This makes suitable for brief interventions like peripheral nerve blocks or epidural use in , where rapid offset is advantageous. Propoxycaine, with a propoxy group at the ortho position, exhibits slower and thus a prolonged duration of action (up to 60-90 minutes), often combined with in dental formulations to balance rapid onset from with extended analgesia from propoxycaine, enhancing overall efficacy without significantly increasing toxicity. Historically, and its derivatives revolutionized by supplanting cocaine's addictive and cardiovascular risks, but 's use has declined in many settings due to its elevated incidence of true allergic reactions—estimated at up to 1% of administrations—stemming from the immunogenic p-aminobenzoic acid moiety, leading to discontinuation in favor of amide-type agents.

Tetracaine and Others

, also known as Pontocaine, is a potent amino ester local anesthetic, chemically 2-(dimethylamino)ethyl 4-(butylamino)benzoate. It exhibits high solubility, with a relative potency value of approximately 10 times that of , enabling effective blockade of sodium channels in neural tissues. This compound is particularly suited for spinal due to its ability to provide profound and prolonged sensory and motor blockade. The extended duration of action, lasting up to 200 minutes, stems from its slower by plasma pseudocholinesterase compared to shorter-acting amino esters like . Among other notable amino esters, benzocaine serves as a key example for topical applications. , chemically ethyl 4-aminobenzoate, functions as a surface by inhibiting voltage-gated sodium channels in superficial nerve endings. Its poor water , approximately 2.4 mM (or 400 mg/L), renders it unsuitable for injectable use and confines its administration to topical formulations such as gels, ointments, and sprays for minor dermal or mucosal analgesia. This low also limits systemic absorption, contributing to its safety profile for superficial procedures. Cocaine represents a historical benchmark in the development of amino ester local anesthetics as a naturally occurring benzoylmethylecgonine . Isolated from leaves in the mid-19th century, it was the first compound recognized for its local anesthetic properties, particularly in ocular and nasal surgeries, due to its vasoconstrictive effects alongside blockade. Although potent, its clinical use has largely been supplanted by safer synthetic alternatives owing to addictive potential and toxicity risks. These compounds collectively illustrate the diversity in potency and application within the amino ester class, with emphasizing injectability for deeper and prioritizing non-invasive relief.

Adverse Effects

Allergic Reactions

Amino ester local anesthetics are associated with a higher risk of reactions compared to types, primarily due to their into para-aminobenzoic acid (PABA), a known . True IgE-mediated (type I) allergies to these agents occur in approximately 1% of cases, though adverse reactions overall are reported in 0.1-1% of administrations. While true type I reactions are rare, () to PABA metabolites is more frequent with amino esters. Symptoms of these allergic reactions typically include urticaria, , , and in severe cases, . Cross-reactivity is common with antibiotics and PABA-containing products such as certain sunscreens, due to structural similarities that can trigger reactions, primarily type IV. Diagnosis involves skin prick testing followed by intradermal testing if initial results are negative, using diluted solutions of the suspected agent to confirm IgE-mediated while minimizing risk. Patients with confirmed allergies or at high risk, such as those with prior PABA exposure, should avoid amino esters entirely, opting for alternatives under medical supervision.

Systemic Toxicity

Systemic toxicity from amino esters, a class of ester-type local anesthetics such as and , arises primarily from excessive plasma concentrations that lead to unintended blockade of sodium channels in non-target tissues, particularly the (CNS) and cardiovascular system. This condition, known as local anesthetic systemic toxicity (LAST), typically occurs due to overdose, inadvertent intravascular injection, or impaired , resulting in pharmacological effects rather than immunological responses. In the CNS, high doses of amino esters inhibit sodium influx in neuronal membranes, initially causing excitatory symptoms such as perioral numbness, , agitation, and muscle twitching, which can rapidly progress to generalized seizures due to preferential depression of inhibitory cortical pathways. Severe cases may lead to and as the anesthetic further depresses CNS function, with seizures reported in approximately 68% of LAST incidents. Cardiovascular manifestations include and , stemming from blockade that impairs cardiac conduction and contractility, as well as direct myocardial depression and peripheral vasodilation. In advanced toxicity, these effects can escalate to ventricular arrhythmias, , or , with cardiovascular collapse occurring in up to 33% of cases. Management of systemic toxicity prioritizes immediate cessation of the , airway support, and seizure control with benzodiazepines such as . For cardiovascular instability refractory to standard , intravenous lipid emulsion therapy (e.g., 20% lipid emulsion with a 1.5 mL/kg bolus followed by infusion) is recommended to sequester the and mitigate effects, as per guidelines from the American Society of Regional Anesthesia. Maximum safe doses are critical to prevent toxicity; for example, is limited to 1 mg/kg without epinephrine to avoid exceeding plasma thresholds. Risk factors exacerbating toxicity include rapid intravenous injection, which can produce symptoms within minutes, and conditions impairing pseudocholinesterase activity, such as hepatic dysfunction or genetic deficiency, which prolong the duration of amino esters in circulation due to their reliance on plasma for .

References

  1. https://www.sciencedirect.com/topics/medicine-and-dentistry/amino-esters
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3417942/
  3. https://www.nysora.com/topics/pharmacology/clinical-pharmacology-local-anesthetics/
  4. https://www.ncbi.nlm.nih.gov/books/NBK430894/
  5. https://www.bjaed.org/article/S2058-5349(19)30152-0/fulltext
  6. https://www.ncbi.nlm.nih.gov/books/NBK610935/
  7. https://www.sciencedirect.com/science/article/abs/pii/S0040402020308358
  8. https://www.woodlibrarymuseum.org/museum/benzocaine/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC8996304/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC7808030/
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC3403589/
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC1693664/
  13. https://www.ncbi.nlm.nih.gov/books/NBK541053/
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC9076432/
  15. https://www.sciencedirect.com/science/article/pii/S0005273612002465
  16. https://emedicine.medscape.com/article/873879-overview
  17. https://pocketdentistry.com/local-anesthetics-4/
  18. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9775567.htm
  19. https://www.chemicalbook.com/ProductChemicalPropertiesCB9296712_EN.htm
  20. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9296712.htm
  21. https://derangedphysiology.com/main/cicm-primary-exam/nervous-system/Chapter-324/pharmacology-local-anaesthetics
  22. https://go.drugbank.com/drugs/DB00721
  23. https://www.researchgate.net/publication/229824609_Hydrolysis_of_Procaine_in_Aqueous_Buffer_Solutions
  24. https://www.sciencedirect.com/science/article/abs/pii/S009595531531951X
  25. https://www.drugs.com/monograph/benzocaine-topical.html
  26. https://globalrph.com/drugs/local-anesthetics/
  27. https://pubmed.ncbi.nlm.nih.gov/19967781/
  28. https://www.drugs.com/monograph/local-anesthetics-parenteral-general-statement.html
  29. https://www.masterorganicchemistry.com/2022/10/27/saponification-of-esters/
  30. https://www.sciencedirect.com/science/article/pii/S0040402020308358
  31. https://patents.google.com/patent/EP0492494A1/en
  32. https://chem.libretexts.org/Ancillary_Materials/Laboratory_Experiments/Wet_Lab_Experiments/Organic_Chemistry_Labs/The_Synthesis_and_Characterization_of_Carbonyl_Compounds/3%3A_Esterification_%28Experiment%29
  33. https://learn.openochem.org/learn/the-alchemy-of-drug-development/from-cocaine-to-novocain-the-development-of-safer-local-anesthesia
  34. https://www.fda.gov/files/drugs/published/Q7-Good-Manufacturing-Practice-Guidance-for-Active-Pharmaceutical-Ingredients-Guidance-for-Industry.pdf
  35. https://www.beilstein-journals.org/bjoc/articles/11/134
  36. https://www.nbinno.com/article/pharmaceutical-intermediates/sourcing-high-purity-procaine-hcl-manufacturers-guide-af
  37. https://www.sciencedirect.com/science/article/abs/pii/S0026265X21005828
  38. https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs961-annex6-gmp-sterile-pharmaceutical-products.pdf
  39. https://pubmed.ncbi.nlm.nih.gov/16101448/
  40. https://academic.oup.com/bja/article/89/1/52/256293
  41. https://pubs.rsc.org/en/content/articlehtml/2019/ra/c9ra09287k
  42. https://www.sciencedirect.com/science/article/pii/S0889853705701619
  43. https://www.ncbi.nlm.nih.gov/books/NBK551556/
  44. https://www.ncbi.nlm.nih.gov/books/NBK535437/
  45. https://emedicine.medscape.com/article/149178-overview
  46. https://pubmed.ncbi.nlm.nih.gov/573562/
  47. https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=c80c810a-60e0-49bd-139c-95aec3a286fc&type=pdf
  48. https://www.ncbi.nlm.nih.gov/books/NBK532901/
  49. https://decisionsindentistry.com/article/update-on-dental-topical-anesthetics/
  50. https://eyewiki.org/Anesthesia_for_Oculoplastic_Surgery
  51. https://iowaprotocols.medicine.uiowa.edu/protocols/maximum-recommended-doses-and-duration-local-anesthetics
  52. https://reference.medscape.com/drug/pontocaine-tetcaine-tetracaine-343373
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC8349289/
  54. https://pubchem.ncbi.nlm.nih.gov/compound/Procaine
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC10949376/
  56. https://aneskey.com/local-anesthetics-16/
  57. https://go.drugbank.com/drugs/DB09342
  58. https://pubmed.ncbi.nlm.nih.gov/6942010/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC4173488/
  60. https://www.sciencedirect.com/science/article/pii/S0022356525278776
  61. https://pubchem.ncbi.nlm.nih.gov/compound/Benzocaine
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC11322916/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC5564188/
  64. https://pubchem.ncbi.nlm.nih.gov/compound/Cocaine
  65. https://pubmed.ncbi.nlm.nih.gov/11895133/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197930/
  67. https://www.dovepress.com/risk-of-true-allergy-to-local-anesthetics-10-year-experience-from-an-a-peer-reviewed-fulltext-article-TCRM
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC5586559/
  69. https://www.bjanaesthesia.org.uk/article/S0007-0912(17)32181-5/fulltext
  70. https://www.researchgate.net/publication/9008256_Allergies_to_local_anesthetics_-_The_real_truth
  71. https://dermnetnz.org/topics/allergy-to-paba
  72. https://www.ejpd.eu/pdf/EJPD_2019_20_1_10.pdf
  73. https://www.bjanaesthesia.org.uk/article/S0007-0912%2817%2932181-5/fulltext
  74. https://www.ncbi.nlm.nih.gov/books/NBK499964/
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC6087022/
Add your contribution
Related Hubs
User Avatar
No comments yet.